arrow
E

Eleni Lagkadinou

Beth Israel Deaconess Medical Center
H指数:13
被引数:1,934

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

BNT162b2 mRNA疫苗在中国成年人中的免疫原性和安全性: 一项2期随机临床试验

2022-12-0112
OAAI
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial

中国成年人SARS-CoV-2接种BNT162b1 mRNA疫苗后的免疫持久性和安全性: 一项随机、安慰剂对照、双盲1期试验

2022-06-306
OAAI
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

靶向PD-L1和4-1BB (GEN1046) 的双特异性抗体在晚期难治性实体瘤患者中的临床前特征和I期试验结果

2022-02-1761
OAAI
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
2022-01-06432
OAAI
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
2021-10-21276
OAAI
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
2021-04-22103
PREAI
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
2021-01-06156
OAAI
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
LEUKEMIA
IF13.4
2020-07-3039
OAAI
Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL
2018-07-011
PRE